• 1. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 2. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 5. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693

Professional Introduction to 3-Bromo-5-(pyrrolidin-1-yl)pyridine (CAS No. 944718-19-8)

3-Bromo-5-(pyrrolidin-1-yl)pyridine (CAS No. 944718-19-8) is a significant compound in the field of pharmaceutical chemistry, playing a crucial role in the synthesis and development of various bioactive molecules. This compound, characterized by its brominated pyridine core and pyrrolidine substituent, has garnered considerable attention due to its versatile applications in medicinal chemistry and drug discovery.

The structural motif of 3-Bromo-5-(pyrrolidin-1-yl)pyridine makes it an attractive intermediate for constructing complex pharmacophores. The bromine atom at the 3-position provides a reactive site for further functionalization via cross-coupling reactions, such as Suzuki-Miyaura, Buchwald-Hartwig, and Heck couplings. These reactions are fundamental in the assembly of heterocyclic scaffolds, which are prevalent in many therapeutic agents.

The pyrrolidine moiety, on the other hand, is a common pharmacophore found in numerous drugs due to its ability to enhance binding affinity and metabolic stability. In recent years, there has been a surge in research focused on developing small molecules with pyrrolidine derivatives as key structural components. These compounds have shown promise in various therapeutic areas, including oncology, neurology, and anti-inflammatory applications.

One of the most compelling aspects of 3-Bromo-5-(pyrrolidin-1-yl)pyridine is its utility in the synthesis of kinase inhibitors. Kinases are enzymes that play a pivotal role in cell signaling pathways and are frequently targeted in anticancer therapies. The brominated pyridine scaffold allows for the introduction of additional functional groups that can modulate the selectivity and potency of kinase inhibitors. For instance, recent studies have demonstrated the efficacy of pyridine-based inhibitors in targeting tyrosine kinases, which are aberrantly activated in many cancer types.

In addition to its role in kinase inhibition, 3-Bromo-5-(pyrrolidin-1-yl)pyridine has been explored in the development of antiviral agents. The pyrrolidine ring can interact with viral proteases and polymerases, disrupting viral replication cycles. A notable example is the use of pyridine derivatives in inhibiting HIV protease, a key enzyme required for viral maturation. The bromine substituent facilitates further derivatization, enabling the optimization of drug-like properties such as solubility and bioavailability.

The compound's potential extends beyond oncology and virology; it has also been investigated for its anti-inflammatory properties. Inflammatory pathways are dysregulated in various chronic diseases, including rheumatoid arthritis and inflammatory bowel disease. Pyrrolidine-containing molecules have shown promise in modulating these pathways by inhibiting key inflammatory mediators. Preclinical studies have highlighted the therapeutic potential of 3-Bromo-5-(pyrrolidin-1-yl)pyridine-based analogs in reducing inflammation and alleviating symptoms associated with these conditions.

The synthesis of 3-Bromo-5-(pyrrolidin-1-yl)pyridine typically involves multi-step organic transformations starting from commercially available precursors. A common synthetic route includes the bromination of a pyridine derivative followed by nucleophilic substitution with a pyrrolidine equivalent. Advances in catalytic systems have improved the efficiency and scalability of these reactions, making it feasible to produce larger quantities for research and industrial applications.

The growing interest in this compound underscores its importance as a building block in drug discovery. Researchers are continuously exploring new ways to leverage its structural features for developing novel therapeutics. Collaborative efforts between academia and industry are driving innovation, leading to the identification of new applications and optimizing existing ones.

In conclusion, 3-Bromo-5-(pyrrolidin-1-yl)pyridine (CAS No. 944718-19-8) is a versatile compound with significant implications in pharmaceutical chemistry. Its unique structural features make it invaluable for synthesizing bioactive molecules targeting various diseases. As research progresses, we can expect to see further advancements leveraging this compound's potential, contributing to the development of next-generation therapeutics.

• 223796-92-7(1-(3-Bromo-5-pyridyl)homopiperazine)
• 1255957-53-9((5-Bromo-pyridin-3-yl)-diethyl-amine)
• 24255-93-4(3-bromo-5-(piperidin-1-yl)pyridine)
• 675594-08-8(1,4-DIAZABICYCLO[3.3.3]UNDECANE, 4-(5-BROMO-3-PYRIDINYL)-)
• 1643562-61-1(3-Bromo-5-(diethylamino)pyridine-d13)
• 1289153-40-7(3-Bromo-5-(2-methylpiperidin-1-yl)pyridine)
• 1289198-33-9(3-Bromo-5-(3-methylpiperidin-1-yl)pyridine)
• 1289078-59-6(5-Bromo-N-butylpyridin-3-amine)
• 1289048-18-5(3-Bromo-5-(4-methylpiperidin-1-yl)pyridine)
• 847406-25-1(4-PIPERIDINAMINE, 1-(5-BROMO-3-PYRIDINYL)-)